Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Biotechnology

Healthcare
$10.17 -1.58%

-$0.19 today

Market cap
$857.87M
Beta
0.84
P/E (TTM)
-24.1
EPS (TTM)
-$0.49
52W Low $3.55High $26.95

Volume 0.93M

Average 1.49M

CRVS EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

Corvus Pharmaceuticals, Inc.NASDAQ: CRVS

EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026

EPS (Basic) turns negative

Q1 FY2026 EPS (Basic) was -$0.15, compared with $0.21 a year earlier. Trailing-twelve-month EPS (Basic) was -$0.55.

Context

  • EPS (Basic) grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EPS (Basic) reaches the consensus estimate from 4 analysts of -$0.68 (-258.3%) for the fiscal year ending Dec 2026, a slowdown from the +81.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$0.15+16.7% QoQ
Last fiscal yearDec 2025
-$0.19+81.4% YoY
LTMMar 2026
-$0.55+14.1% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-171.4%-59.2%+112.2 pp
1 year+81.4%-258.3%-339.7 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Basic) history

USD · from the income statement

Latest · FY2025
(0.19) USD
Year-over-year change
+81.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Basic) vs competitors

How CRVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +14.1% is the 3rd highest of 9, against a peer median of -9.4%.
CRVS Competitors
EPS (Basic) for CRVS and competitors
Company Period LTM YoY 3-year CAGR
CGENCompugen Ltd.LTM Mar 2026$0.37 USD+335.9%—
CTMXCytomX Therapeutics, Inc.LTM Mar 2026-$0.36 USD-172.2%—
CMPXCompass Therapeutics, Inc.LTM Mar 2026-$0.43 USD-5.9%—
IPHAInnate Pharma S.A.FY2025-€0.53 EUR+13.1%—
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$0.55 USD+14.1%—
ADAGAdagene Inc.LTM Jun 2024-$0.9 USD——
MGNXMacroGenics, Inc.LTM Mar 2026-$1.1 USD-23.6%—
CHRSCoherus Oncology, Inc.LTM Mar 2026-$1.28 USD-12.9%—
RCUSArcus Biosciences, Inc.LTM Jun 2026-$3.93 USD-20.6%—
NKTRNektar TherapeuticsLTM Jun 2026-$6.7 USD+23.1%—
Peer median (excluding CRVS) —-9.4%—

Competitors are the stored peer set for CRVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000105K
Gross Profit0000(105K)
Gross Margin—————
Research & Development29.12M24.47M16.53M19.39M33.72M
Selling, General & Admin9.52M8.1M6.88M8.16M9.25M
Operating Expenses38.63M32.57M23.41M27.55M42.87M
Depreciation & Amortization460K367K151K85K105K
EBITDA(42.77M)(40.94M)(26.88M)(62.21M)(15.18M)
EBITDA Margin—————
Operating Income(38.63M)(32.57M)(23.41M)(27.55M)(42.97M)
Operating Margin—————
Interest Income0654K1.58M1.82M2.51M
Interest Expense15K0000
Other Income / Expenses(4.61M)(8.74M)(3.62M)(34.75M)27.69M
Income Before Tax(43.24M)(41.31M)(27.03M)(62.29M)(15.28M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(43.24M)(41.31M)(27.03M)(62.29M)(15.28M)
Net Margin—————
EPS (Basic)(1.03)(0.89)(0.56)(1.02)(0.19)
EPS (Diluted)(1.03)(0.89)(0.56)(1.02)(0.53)
Weighted Avg Shares41.85M46.55M48.03M60.99M78.96M
Weighted Avg Shares (Diluted)41.85M46.55M48.03M60.99M79.74M

Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Intrinsic Alpha fair value

Locked

Current Price

$10.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.